AI in multi-omics analysis of type 2 diabetes

The integration of multi-omics technologies has significantly advanced the understanding of the complex and multifactorial pathophysiology of Type 2 Diabetes. In contrast to traditional single-omics approaches, multi-omics integration enables a comprehensive, systems-level characterization of molecular interactions, regulatory mechanisms, and disease progression pathways. This holistic framework facilitates the discovery of novel biomarkers, early diagnostic signatures, and actionable therapeutic targets by linking molecular variations with clinical phenotypes. However, the high dimensionality, heterogeneity, and scale of multi-omics data present substantial analytical challenges. Recent advances in artificial intelligence (AI) have addressed these limitations by providing powerful computational tools for effective data integration, pattern recognition, and predictive modeling. AI-driven approaches, particularly deep learning architectures, enable automated feature extraction and nonlinear relationship mapping across omics layers, thereby improving disease risk prediction and patient stratification. Collectively, the convergence of AI and multi-omics is transforming diabetes research toward predictive, preventive, and personalized healthcare paradigms.